Evidence map›Paper›PMID 31303174›Full record

ArticleInfectious diseases of poverty2019

The need for evidence-based strategies and tools for onchocerciasis elimination in Africa.

Yankum Dadzie, Uche V Amazigo, Boakye A Boatin, Azodoga Sékétéli

Abstract readLetter
In one paragraph

Article in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yankum Dadzie, P. O. Box OS-1905, Accra, Ghana. yankumdadzie@iname.com.
Uche V Amazigo, P. O. Box 3397, Main Post Office, Okpara Avenue, Enugu, Nigeria.
Boakye A Boatin, P.O Box CT 1380, Accra, Ghana.
Azodoga Sékétéli, Lomé 01, BP 3841, Togo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent article we discussed the feasibility of onchocerciasis elimination in Africa by 2025. We expressed concern that elimination may be impeded by failure to build on the lessons learned in the African onchocerciasis control programmes and the introduction of strategies and tools from the Americas. Richards et al. and Cupp et al. wrote to refute our concern and described recent achievements with stopping treatment in some areas.In this response, we discuss their arguments which did not convince us. We point out several scientific flaws in the American conceptual framework of elimination which has led to longer periods of treatment than necessary, and in the use of an arbitrary threshold for stopping treatment. We show that recent achievements fall significantly short of what would be needed to achieve onchocerciasis elimination by 2025.We conclude our response by advocating for a more objective and inclusive debate on strategies and tools for onchocerciasis elimination.

Indexed as

AfricaAnimalsDisease EradicationFilaricidesHumansIvermectinMass Drug AdministrationOnchocerca volvulusOnchocerciasis, OcularFilaricidesIvermectinConceptual frameworkEliminationIvermectinOnchocerciasisVector control

Identifiers

PMID31303174
PMCPMC6628483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.